Literature DB >> 31970592

Correction to: Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.

Satoru Kuriyama1,2.   

Abstract

In the original publication of the article the presentation of Table 1 was incorrectly published.

Entities:  

Year:  2020        PMID： 31970592     DOI： 10.1007/s10157-020-01845-4

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN： 1342-1751            Impact factor:   2.801


  2 in total

1.  A κ-OR Agonist Protects the Endothelial Function Impaired by Hyperuricemia Through Regulating the Akt/eNOS Signal Pathway.

Authors:  Qin Zheng; Qi Wu; Hong Yang; Qiuhong Chen; Xiaohui Li; Jingyi Guo
Journal:  Probiotics Antimicrob Proteins       Date:  2022-05-10       Impact factor: 4.609

Review 2.  Review of Urate-Lowering Therapeutics: From the Past to the Future.

Authors:  Christopher Jenkins; Jennifer H Hwang; Jeffrey B Kopp; Cheryl A Winkler; Sung Kweon Cho
Journal:  Front Pharmacol       Date:  2022-08-23       Impact factor: 5.988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.